Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome

by Palobiofarma

Palobiofarma S.L., una empresa biofarmacéutica dedicada al descubrimiento y desarrollo de fármacos innovadores para enfermedades huérfanas, ha anunciado hoy el logro de varios hitos importantes en ...

Read more

GENESIS Biomed participated in the strategic development of AptaTargets, which has licensed its drug ApTOLL to Merck

by GENESIS Biomed

AptaTargets signed in May 2025 a licensing agreement with Merck for the clinical development and global commercialisation of ApTOLL, an aptamer with neuroprotective effect for the treatment of ischaem...

Read more

Application of Biomarkers in Bioanalytics: Enabling Translational Development in Pharmaceutical R&D

by AMSbiopharma

In bioanalytical workflows, biomarkers serve as quantifiable proxies for biological processes, disease states, or therapeutic responses. Still, the rapid evolution of drug discovery and clinical devel...

Read more

ORYZON announces First‑Patient‑In (FPI) in RESTORE Phase Ib trial of iadademstat in sickle cell disease

by Oryzon Genomics

Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCD

Read more

Pharma workflow automation mistakes that trigger audit findings

by Rubió

Automation in pharma promises faster cycles, cleaner records, and lower cost. It can deliver. But the same digital workflows that cut review time from fourteen days to five can also manufacture findin...

Read more

ORYZON announces positive clinical data of iadademstat at ASH-2025

by Oryzon Genomics

Preliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rate

Read more

ORYZON reports financial results and corporate update for quarter ended September 30, 2025

by Oryzon Genomics

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green

Read more

53Biologics, galardonada con el premio pyme del año 2025 de Valladolid

by 53Biologics

53Biologics ha sido distinguida hoy con el Premio Pyme del Año 2025 de Valladolid, un reconocimiento otorgado por Banco Santander y la Cámara de Comercio de Valladolid, en colaboración con la Cáma...

Read more

Joan Puig – CEO at Kymos Group

by GENESIS Biomed

Joan Puig: “In inorganic growth in Europe, cultural difference is one of the most important challenges”.

Read more

How biotechnology is reshaping pharmaceutical manufacturing: key insights from Klinea’s expert round table

by Asebio

Biotechnology is rapidly transforming the pharmaceutical landscape—yet its industrialisation presents challenges that require coordinated technical, regulatory and strategic action.

Read more

Oniria Therapeutics, VHIO and ICIQ awarded over €1.7 million from Spanish Ministry of Science and Innovation to advance ONR-001 drug targeting resistant colon cancer

by ONIRIA Therapeutics

Biopharmaceutical company Oniria Therapeutics, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) will work together on the regulatory preclinical phas...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Researchers Discover How Acute Myeloid L...

by Institut de Recerca Sant Pau

Acute myeloid leukemia (AML) does more than infiltrate the lungs: it a...

Photos Stream